Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma
1996

High-Dose IL-2 and IFN-alpha Treatment for Metastatic Melanoma

Sample size: 43 publication Evidence: moderate

Author Information

Author(s): WHJ Kruit, CJA Punt, SH Goey, PHM de Mulder, JW Gratama, AMM Eggermont, RLH Bolhuis, G Stoter

Primary Institution: Rotterdam Cancer Institute and University Hospital

Hypothesis

Does a 5-day schedule of high-dose IL-2 and IFN-alpha lead to better outcomes than a 3-day schedule in treating metastatic melanoma?

Conclusion

The 5-day treatment schedule had a higher response rate but caused severe toxicity, while the 3-day schedule had manageable toxicity but a lower response rate.

Supporting Evidence

  • The 5-day schedule resulted in a 41% response rate.
  • The 3-day schedule had a 20% response rate.
  • Severe cardiotoxicity occurred in 41% of patients on the 5-day schedule.
  • Neuropsychiatric disturbances were reported in two-thirds of patients on the 5-day regimen.
  • All patients provided informed consent and the study had ethical approval.

Takeaway

Doctors tested two different treatment schedules for melanoma, and while one worked better, it also caused more side effects.

Methodology

Patients were treated with either a 5-day or 3-day schedule of IL-2 and IFN-alpha, and their responses and side effects were monitored.

Potential Biases

Potential bias due to non-randomized design and patient selection criteria.

Limitations

The study was not randomized, making direct comparisons between the two schedules difficult.

Participant Demographics

Patients aged 18-70 with histologically confirmed metastatic melanoma.

Statistical Information

Confidence Interval

95% CI 18-67% for 5-day schedule; 95% CI 7-43% for 3-day schedule

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication